Avanos Medical, Inc. (AVNS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported strong financial performance with record high revenue and raised guidance for both revenue and EPS. Despite the divestiture impact, the acquisition of Nexus Medical is accretive, and strategic transitions are underway to mitigate tariff impacts. The Q&A indicates confidence in continued growth and operating leverage, although some management responses lacked clarity. Overall, the sentiment leans positive due to robust financial metrics and optimistic guidance.
Key Financial Performance
Full Year Net Sales $701 million, exceeding the revised range following Q3. This growth was driven by strong execution of commercial teams.
Adjusted Diluted Earnings Per Share (Full Year) $0.94. The impact of tariffs in 2025 obscured profitability, but mitigation steps were taken.
Specialty Nutrition Systems Portfolio Growth Over 8% organically year-over-year. Growth was driven by strong demand for long-term enteral feeding products and double-digit growth in short-term enteral feeding portfolio globally.
Pain Management and Recovery Portfolio Growth Normalized organic sales up 2.3% year-over-year, excluding foreign exchange and strategic withdrawal from low-growth, low-margin products. Radiofrequency ablation business posted double-digit organic growth.
Fourth Quarter Net Sales Approximately $181 million. Organic sales for strategic segments were up 3.4% year-over-year, adjusted for foreign exchange and strategic decisions.
Fourth Quarter Adjusted Diluted Earnings Per Share $0.29.
Fourth Quarter Adjusted EBITDA $28 million.
Fourth Quarter Adjusted Gross Margin 53.4%.
Fourth Quarter Adjusted SG&A as Percentage of Revenue 39.1%.
Full Year Adjusted Organic Sales Growth (Strategic Segments) Up 6% year-over-year, reflecting strength in Specialty Nutrition Systems and improving trends in Pain Management and Recovery.
Full Year Adjusted EBITDA $87 million.
Full Year Adjusted Gross Margin 54.6%.
Full Year Adjusted SG&A as Percentage of Revenue 42%.
Specialty Nutrition Systems Operating Profit (Full Year) 19%, down 100 basis points year-over-year due to unfavorable tariff impacts despite higher sales volume.
Pain Management and Recovery Operating Profit (Full Year) 4%, a 270-basis point improvement year-over-year, driven by top-line and cost management execution despite unfavorable tariff costs.
Hyaluronic Acid Injections and IV Therapy Product Lines Decline Over 35% year-over-year, primarily due to the divestiture of the HA business.
Free Cash Flow (Fourth Quarter) $21 million.
Free Cash Flow (Full Year) $43 million, higher than anticipated due to timing of one-time cash charges and tax payments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Specialty Nutrition Systems (SNS): Delivered strong above-market full year results, growing over 8% organically. Short-term enteral feeding portfolio posted double-digit global growth. Long-term feeding grew high single digits, supported by U.K. Go-Direct transition. Neonatal solutions business delivered above-market performance, growing over 6%.
Pain Management and Recovery: Normalized organic sales grew 2.3%. Radiofrequency ablation (RFA) business posted double-digit organic growth. Surgical pain business declined due to delayed impact of NOPAIN Act. GAME READY portfolio remained stable year-over-year.
New Product Launches: Adoption of CORGRIP 2 retention system launched in late 2024 contributed to short-term feeding momentum.
Geographic Expansion: U.K. Go-Direct transition supported growth in long-term enteral feeding. COOLIEF offering expanded internationally, leveraging reimbursement tailwinds in the U.K. and Japan.
Tariff Mitigation: Implemented internal cost containment, pricing actions, and extended temporary tariff exemptions. Successfully executing China exit strategy for syringe manufacturing, expected completion by June 2026.
Cost Efficiencies: Initiatives implemented in late 2025 expected to drive ongoing cost improvements in 2026 and beyond.
Portfolio Management: Divested hyaluronic acid business, exited GAME READY rental business, acquired Nexus Medical, and announced exit of IV therapy business. Nexus integration progressing well, driving adoption and growth.
Strategic Imperatives: Focused on accelerating organic growth, mitigating tariffs, realizing operating efficiencies, improving/divesting underperforming assets, and pursuing synergistic acquisitions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Impact: Ongoing tariffs have obscured profitability in 2025, and the company faces $30 million in tariff-related costs in 2026, a $12 million increase from 2025. The majority of these costs are tied to neonatal products sourced from China. While mitigation efforts are underway, the full exit from China is not expected until mid-2026.
NOPAIN Act Implementation: The implementation of reimbursement under the NOPAIN Act is taking longer than anticipated, negatively impacting the surgical pain business.
GAME READY Portfolio: The GAME READY portfolio experienced a year-over-year decline in revenue, and while efforts to enhance profitability are in place, the segment remains underperforming.
Foreign Exchange Impact: Foreign exchange fluctuations have impacted normalized organic sales growth, particularly in the Pain Management and Recovery portfolio.
IV Therapy Business Exit: The company is managing the IV therapy product line for cash and plans to fully exit this category in Q1 2026, which could result in short-term revenue loss.
Hyaluronic Acid Business Divestiture: The divestiture of the hyaluronic acid business has led to a 35% decline in revenue for the Corporate and Other segment.
Supply Chain Transition: The transition of syringe manufacturing operations from China to Mexico and Southeast Asia involves higher capital expenditures and operational risks during the transition period.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Organic Sales Growth: Mid-single-digit organic sales growth expected in strategic segments.
Operating Margin Improvement: Anticipated improvement in operating margin despite incremental unfavorable tariff expenses.
Gross Margin Momentum: Pause in gross margin improvement expected in 2026 due to tariffs, with favorable momentum beginning in the second half and continuing into 2027.
Net Sales Guidance: Net sales projected in the range of $700 million to $720 million.
Segment Growth Projections: SNS segment expected to grow mid- to high single digits organically; PM&R segment expected to grow low to mid-single digits organically.
Corporate and Other Revenue: Revenue within Corporate and Other expected to be approximately $1 million as the IV therapy business is fully exited in Q1 2026.
Foreign Exchange Rates: Expected to remain near current levels in 2026.
Adjusted Diluted Earnings Per Share: Guidance set at $0.90 to $1.10 for 2026.
Tariff Costs: Full-year tariff P&L costs expected to be approximately $30 million, a $12 million increase from 2025.
Capital Expenditures: Projected in the range of $25 million, $7 million lower than 2025, to support the accelerated China exit plan.
China Exit Plan: Plan to fully exit China for syringe portfolio by June 2026, with production shifting to Tijuana, Mexico, and Southeast Asia.
Effective Tax Rate: Annual effective tax rate anticipated to be about 29%.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the estimated impact of tariffs for 2026, and what measures are being taken to mitigate this impact?
A:The estimated impact of tariffs for 2026 is roughly $30 million. Measures to mitigate this include cost reductions, price increases, and transitioning production to Mexico and Cambodia. Approximately two-thirds of the $30 million impact is related to China. The company has also received exemptions under the Nairobi protocol for long-term feeding tubes and USMCA for 60%-70% of products made in Mexico.
Q:What is the organic normalized growth rate for the full company and its segments for the year?
A:The organic normalized growth rate is around 5% at the consolidated level. By segment, it is mid- to high single digits for SNS and low to mid-single digits for PM&R.
Q:How confident is the company in continuing to drive operating leverage in 2026, and what are the plans for R&D and cost management?
A:The company has a high degree of confidence in driving operating leverage in 2026. Plans include launching a next-generation product in Q4, managing costs efficiently, and evaluating underperforming businesses for improvement or divestiture. R&D spending will remain consistent as a percentage of sales, with more projects outsourced. Cost containment measures and sales volume growth are expected to offset additional expenses like the $12 million tariff expense.
Q:What is driving the strong performance in the Specialty Nutrition segment, and what are the expectations for Nexus in 2026?
A:Strong demand for the SNS portfolio, market penetration with CORTRAK, and a strong neonatal business are driving performance. Nexus is performing better than expected, contributing $5 million in revenue last year and expected to grow in double digits in 2026 and beyond.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding specific milestones for the transition of China or detailed impacts of the Supreme Court ruling and administration changes on tariffs. Their responses were vague and lacked clarity on these aspects.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act GAME
Avanos
China
GAME READY
GAME portfolio
IV therapy
NOPAIN Act
Nutrition Systems
Pain Recovery
Scott
Specialty Nutrition
ability sale
action
digit
effort cost
exchange
exit
imperative
improvement tariff
integration Nexus
margin improvement
portfolio capital
product line
profitability
proposition
ruling
sale segment
share tariff
syringe
term feeding
therapy product
AVNS Transcript
Avanos Medical, Inc. (AVNS) Presents at The Citizens Life Sciences Conference 2026 Transcript
Neutral3-11
Avanos Medical, Inc. (AVNS) Q4 2025 Earnings Call Transcript
Positive2-24
The company reported strong financial performance with record high revenue and raised guidance for both revenue and EPS. Despite the divestiture impact, the acquisition of Nexus Medical is accretive, and strategic transitions are underway to mitigate tariff impacts. The Q&A indicates confidence in continued growth and operating leverage, although some management responses lacked clarity. Overall, the sentiment leans positive due to robust financial metrics and optimistic guidance.
Avanos Medical, Inc. (AVNS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Wesdome Gold Mines Ltd. (WDO:CA) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call reveals strong financial performance, including a 57% revenue increase and doubled net income. The company is addressing operational challenges, such as ramp development delays and labor issues, with strategic plans. The Q&A section highlights proactive measures and positive guidance updates, despite some concerns about management's clarity. The opportunistic share repurchase plan and improved cash position further boost sentiment. Overall, the financial health and strategic initiatives suggest a positive stock price movement, though not strongly positive due to ongoing operational risks.
AVNS Slides
AVNS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
